Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Cash from Financing Activities (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Cash from Financing Activities for 7 consecutive years, with -$3000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Cash from Financing Activities fell 100.25% to -$3000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $29.3 million, a 97.18% increase, with the full-year FY2024 number at $29.3 million, up 97.18% from a year prior.
  • Cash from Financing Activities was -$3000.0 for Q4 2024 at Actinium Pharmaceuticals, down from $4.6 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $16.7 million in Q2 2022 to a low of -$22000.0 in Q1 2022.
  • A 4-year average of $6.4 million and a median of $4.7 million in 2022 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: surged 3600.0% in 2023, then crashed 100.25% in 2024.
  • Actinium Pharmaceuticals' Cash from Financing Activities stood at $801000.0 in 2021, then skyrocketed by 510.86% to $4.9 million in 2022, then plummeted by 75.64% to $1.2 million in 2023, then plummeted by 100.25% to -$3000.0 in 2024.
  • Per Business Quant, the three most recent readings for ATNM's Cash from Financing Activities are -$3000.0 (Q4 2024), $4.6 million (Q3 2024), and $10.0 million (Q2 2024).